Production System for 18-Labeled Oxygen

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$993,912.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK085817-02
Award Id:
n/a
Agency Tracking Number:
R44DK085817
Solicitation Year:
2012
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA11-096
Small Business Information
2 Park Drive, Unit 4, Westford, MA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
101061500
Principal Investigator:
MICHAEL KIMBLE
(978) 692-4664
mkimble@reactive-innovations.com
Business Contact:
MICHAEL KIMBLE
(978) 692-4664
mkimble@reactive-innovations.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The National Institutes of Health desires to have more economical methods to produce 18-labeled oxygen and, in particular, 18-labeled water for use in energy expenditure and body composition studies. This oxygen-18 is converted into fluorinated-18 isotopes to produce radiopharmaceuticals for medical imaging using Positron Emission Tomography (PET). The availability of the 18-labeled water feedstock is limited, costly, and with the growth in new radiopharmaceuticals, thisfeedstock will soon not be able to meet the demand. Thus, there is an urgent need to recycle the spent singly labeled water during cyclotron operations used to produce the radiopharmaceuticals. During a Phase I program, Reactive Innovations, LLC demonstrated a new process to recover and purify the oxygen-18 labeled water used in producing these radiopharmaceuticals. With this system, a higher conversion yield is possible for converting the singly labeled water into fluorinated-18 compounds. This helps themedical imaging profession increase the use of PET for medical diagnostics, lowers the costs for the expensive radiopharmaceuticals, and maintains a sufficient supply of radiopharmaceuticals to sustain the rapidly growing usage of PET. During the Phase IIprogram, Reactive Innovations and its commercialization partner will develop and integrate this water recovery and purification process into existing radiopharmaceutical facilities. PUBLIC HEALTH RELEVANCE: Positron Emission Tomography (PET) using[F-18] fluorodeoxyglucose (FDG) as well as other fluorine-18 based radiopharmaceuticals is a rapidly growing diagnostic imaging tool for assessing glucose metabolism in the heart, lungs, and brain, as well as for imaging tumors in oncology. Central to thesuccess of PET is converting the limited supply of the expensive oxygen-18 labeled water feedstock into these fluorinated-18 compounds without discarding the spent water. Reactive Innovations, LLC has demonstrated a new economical method to process and reuse this O-18 water minimizing PET/FDG costs for patients as well as meeting the growing demand for F-18 products used in PET.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government